The efficacy and tolerability of lacosamide adjunctive therapy in children with drug-refractory epilepsy: A nationwide Turkish cohort study
Epilepsy & Behavior · 2026-06 · 179 · 111015
DOI: 10.1016/j.yebeh.2026.111015 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Epilepsy & Behavior, 2026-06. Verfasst von Pinar Ozkan Kart und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Trabzon Kanuni Training and Research Hospital, Trabzon, Türkiye. Electronic address: drpinar_ozkan@yahoo.com. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Resistant Epilepsy, Acetamides. Die Arbeit nennt 41 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
OBJECTIVE To evaluate the efficacy and tolerability of lacosamide (LCM) adjunctive therapy in a nationwide pediatric epilepsy cohort, including drug-refractory epilepsies (DREs). METHODS A retrospective nationwide Turkish cohort study included 334 pediatric epilepsy patients (aged 1-18 years) treated with LCM adjunctive therapy. The population was divided into the two cohorts: (I) DREs with developmental and epileptic encephalopaties (DEEs); early-onset DEEs (group A) and late-onset DEEs (group B), and (II) DRE without DEEs: focal/generalized electroclinical syndromes (group C) and well-defined epilepsy syndromes (group D). The effectiveness of LCM adjunctive therapy was assessed by seizure outcome (seizure freedom, ≥50% reduction, 50% improvement, complete improvement, or worsening). Tolerability was evaluated via drug retention rate and treatment-emergent adverse events (TEAEs). RESULTS The mean duration of LCM adjunctive therapy was 24.63 ± 20.09 months in the cohort (mean age:13.28 ± 4.71 years; 53.8% male). The mean daily effective dose was 6.95 ± 2.25 mg/kg/day, and the time to effectiveness was 2.09 months. Etiological distribution differed across cohorts (p 50% seizure reduction) of 20.7% (n = 69/334). Cumulative EEG improvement was observed in 33.8% of patients receiving LCM adjunctive therapy, while complete EEG recovery rate was achieved in 6.3%. Similar seizure control rates was identified for DRE with DEEs (28.9%) and DRE without DEEs (35%). Drug retention was 73.9% at 12 months and 67.7% at 24 months, while TEAEs occurred in 20.7%, most commonly somnolence (10.4). CONCLUSIONS LCM adjunctive therapy was associated with favorable electro-clinical outcomes and good tolerability across a broad spectrum of DREs with DEEs or without DEEs in childhood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Neurology, Trabzon Kanuni Training and Research Hospital, Trabzon, Türkiye. Electronic address: drpinar_ozkan@yahoo.com.
- Department of Pediatric Neurology, Gazi University, Faculty of Medicine, Ankara, Türkiye. Electronic address: esra.serdaroglu@gmail.com.
- Department of Pediatric Neurology, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Türkiye. Electronic address: nihalyildiz661@hotmail.com.
- Department of Pediatric Neurology, Gazi University, Faculty of Medicine, Ankara, Türkiye. Electronic address: recepkamilkilic@gazi.edu.tr.
- Department of Pediatric Neurology, Akdeniz University, Faculty of Medicine, Antalya, Türkiye. Electronic address: mparesari2@gmail.com.
- Department of Pediatric Neurology, Ankara University, Faculty of Medicine, Türkiye. Electronic address: drsulimen2003@hotmail.com.
Zitieren
APA
Kart, P. O., Serdaroglu, E., Yildiz, N., Kılıç, R. K., Sari, M., Sahin, S., Sen, G., Karaoglu, P., Erdogan, I., Kilic, B., Oztürk, S., Oncel, E. P., Yilmaz, C., Yücel Şen, A. D., Ersoy, O., Kanmaz, S., Yılmaz, S. K., Topcu, Y., Okuyaz, C., …, & Cansu, A. (2026). The efficacy and tolerability of lacosamide adjunctive therapy in children with drug-refractory epilepsy: A nationwide Turkish cohort study. Epilepsy & Behavior, 179, 111015. https://doi.org/10.1016/j.yebeh.2026.111015
Vancouver
Kart PO, Serdaroglu E, Yildiz N, Kılıç RK, Sari M, Sahin S, et al. The efficacy and tolerability of lacosamide adjunctive therapy in children with drug-refractory epilepsy: A nationwide Turkish cohort study. Epilepsy & Behavior. 2026;179:111015. doi:10.1016/j.yebeh.2026.111015
BibTeX
@article{Kart2026,
author = {Kart, Pinar Ozkan and Serdaroglu, Esra and Yildiz, Nihal and Kılıç, Recep Kamil and Sari, Mehpare and Sahin, Suleyman and Sen, Gürsel and Karaoglu, Pakize and Erdogan, Irmak and Kilic, Betul and Oztürk, Selcan and Oncel, Elif Perihan and Yilmaz, Celil and Yücel Şen, Arife Derda and Ersoy, Ozlem and Kanmaz, Seda and Yılmaz, Sanem Keskin and Topcu, Yasemin and Okuyaz, Cetin and Yarar, Coskun and Carman, Kursat Bora and Polat, Muzaffer and Erol, Ilknur and Canpolat, Mehmet and Gümüs, Hakan and Per, Hüseyin and Gencpinar, Pinar and Dundar, Nihal Olgac and Ünalp, Aycan and Ünay, Bülent and Bektaş, Ömer and Teber, Serap and Hirfanoğlu, Tuğba and Arhan, Ebru Petek and Aydin, Kursad and Tekgul, Hasan and Haspolat, Senay and Serdaroglu, Ayse and Cansu, Ali},
title = {The efficacy and tolerability of lacosamide adjunctive therapy in children with drug-refractory epilepsy: A nationwide Turkish cohort study},
journal = {Epilepsy & Behavior},
year = {2026},
volume = {179},
pages = {111015},
doi = {10.1016/j.yebeh.2026.111015}
}
EUVIMED